nach oben

Archivum Immunologiae et Therapiae Experimentalis

Erschienen in:

01.08.2011 | REVIEW

Prevention of Lyme Disease: Promising Research or Sisyphean Task?

verfasst von: Michal Krupka, Katerina Zachova, Evzen Weigl, Milan Raska

Erschienen in: Archivum Immunologiae et Therapiae Experimentalis | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Borrelia burgdorferi sensu lato (Spirochaetes) is a group of at least 12 closely related species, some of which are responsible for chronic zoonotic infection that may cause Lyme disease. The only experimentally confirmed vector transmitting Borrelia to mammals is the Ixodes ticks. Borrelia is a highly adapted pathogen that can survive in the host organism in spite of the intense immune responses. Some patients have chronic long-lasting complications despite antibiotic therapy, probably due to adverse effects of the immune responses. A preventive vaccine against this bacterium has not been available due to the relatively broad spectrum and antigenic variability of Borrelia-surface lipoproteins and the different epitope recognition by experimental animals and humans. Although a human vaccine was marketed in the USA, it has been already pulled off the market. In addition, this vaccine was effective only in the USA, where the only pathogenic species is B. burgdorferi sensu stricto. Recent data indicate that a broadly effective vaccine will to be composed of a mixture of several antigens or multiple epitopes.

Nächster Artikel Soluble TNF-α Receptor I Encoded on Plasmid Vector and Its Application in Experimental Gene Therapy of Radiation-Induced Lung Fibrosis

Alban PS, Johnson PW, Nelson DR (2000) Serum-starvation-induced changes in protein synthesis and morphology of Borrelia burgdorferi. Microbiology 146(Pt 1):119–127PubMed

Alitalo A, Meri T, Ramo L et al (2001) Complement evasion by Borrelia burgdorferi: serum-resistant strains promote C3b inactivation. Infect Immun 69:3685–3691PubMedCrossRef

Anguita J, Ramamoorthi N, Hovius JW et al (2002) Salp15, an Ixodes scapularis salivary protein, inhibits CD4(+) T cell activation. Immunity 16:849–859PubMedCrossRef

Batsford S, Dunn J, Mihatsch M (2004) Outer surface lipoproteins of Borrelia burgdorferi vary in their ability to induce experimental joint injury. Arthritis Rheum 50:2360–2369PubMedCrossRef

Beaufays J, Adam B, Decrem Y et al (2008) Ixodes ricinus tick lipocalins: identification, cloning, phylogenetic analysis and biochemical characterization. PLoS ONE 3:e3941PubMedCrossRef

Belakova J, Krupka M, Sebestova M et al (2005) Preparation and purification of recombinant outer surface protein A (rOspA) of Borrelia burgdorferi sensu stricto and Borrelia afzelii. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149:257–259PubMed

Belakova J, Horynova M, Krupka M et al (2007) DNA vaccines: are they still just a powerful tool for the future? Arch Immunol Ther Exp 55:387–398CrossRef

Bernardino AL, Myers TA, Alvarez X et al (2008) Toll-like receptors: insights into their possible role in the pathogenesis of lyme neuroborreliosis. Infect Immun 76:4385–4395PubMedCrossRef

Boardman BK, He M, Ouyang Z et al (2008) Essential role of the response regulator Rrp2 in the infectious cycle of Borrelia burgdorferi. Infect Immun 76:3844–3853PubMedCrossRef

Bockenstedt LK, Fikrig E, Barthold SW et al (1993) Inability of truncated recombinant Osp A proteins to elicit protective immunity to Borrelia burgdorferi in mice. J Immunol 151:900–906PubMed

Bockenstedt LK, Fikrig E, Barthold SW et al (1996) Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti-OspA IgG in mice. J Immunol 157:5496–5502PubMed

Brandt ME, Riley BS, Radolf JD et al (1990) Immunogenic integral membrane proteins of Borrelia burgdorferi are lipoproteins. Infect Immun 58:983–991PubMed

Brorson O, Brorson SH (1997) Transformation of cystic forms of Borrelia burgdorferi to normal, mobile spirochetes. Infection 25:240–246PubMedCrossRef

Brorson O, Brorson SH (1998a) In vitro conversion of Borrelia burgdorferi to cystic forms in spinal fluid, and transformation to mobile spirochetes by incubation in BSK-H medium. Infection 26:144–150PubMedCrossRef

Brorson O, Brorson SH (1998b) A rapid method for generating cystic forms of Borrelia burgdorferi, and their reversal to mobile spirochetes. APMIS 106:1131–1141PubMedCrossRef

Brown EL, Kim JH, Reisenbichler ES et al (2005) Multicomponent Lyme vaccine: three is not a crowd. Vaccine 23:3687–3696PubMedCrossRef

Buckles EL, Earnhart CG, Marconi RT (2006) Analysis of antibody response in humans to the type A OspC loop 5 domain and assessment of the potential utility of the loop 5 epitope in Lyme disease vaccine development. Clin Vaccine Immunol 13:1162–1165PubMedCrossRef

Burgdorfer W, Barbour AG, Hayes SF et al (1982) Lyme disease—a tick-borne spirochetosis? Science 216:1317–1319PubMedCrossRef

Bykowski T, Woodman ME, Cooley AE et al (2008) Borrelia burgdorferi complement regulator-acquiring surface proteins (BbCRASPs): expression patterns during the mammal-tick infection cycle. Int J Med Microbiol 298(suppl 1):249–256PubMedCrossRef

Cabello FC, Godfrey HP, Newman SA (2007) Hidden in plain sight: Borrelia burgdorferi and the extracellular matrix. Trends Microbiol 15:350–354PubMedCrossRef

Caimano MJ, Eggers CH, Gonzalez CA et al (2005) Alternate sigma factor RpoS is required for the in vivo-specific repression of Borrelia burgdorferi plasmid lp54-borne ospA and lp6.6 genes. J Bacteriol 187:7845–7852PubMedCrossRef

Caimano MJ, Iyer R, Eggers CH et al (2007) Analysis of the RpoS regulon in Borrelia burgdorferi in response to mammalian host signals provides insight into RpoS function during the enzootic cycle. Mol Microbiol 65:1193–1217PubMedCrossRef

Charon NW, Goldstein SF, Marko M et al (2009) The flat-ribbon configuration of the periplasmic flagella of Borrelia burgdorferi and its relationship to motility and morphology. J Bacteriol 191:600–607PubMedCrossRef

Chu HJ, Chavez LG Jr, Blumer BM et al (1992) Immunogenicity and efficacy study of a commercial Borrelia burgdorferi bacterin. J Am Vet Med Assoc 201:403–411PubMed

Comstock LE, Thomas DD (1989) Penetration of endothelial cell monolayers by Borrelia burgdorferi. Infect Immun 57:1626–1628PubMed

Connolly SE, Benach JL (2005) The versatile roles of antibodies in Borrelia infections. Nat Rev Microbiol 3:411–420PubMedCrossRef

Coutte L, Botkin DJ, Gao L et al (2009) Detailed analysis of sequence changes occurring during vlsE antigenic variation in the mouse model of Borrelia burgdorferi infection. PLoS Pathog 5:e1000293PubMedCrossRef

Crother TR, Champion CI, Whitelegge JP et al (2004) Temporal analysis of the antigenic composition of Borrelia burgdorferi during infection in rabbit skin. Infect Immun 72:5063–5072PubMedCrossRef

Dai J, Wang P, Adusumilli S et al (2009) Antibodies against a tick protein, Salp15, protect mice from the Lyme disease agent. Cell Host Microbe 6:482–492PubMedCrossRef

Daix V, Schroeder H, Praet N et al (2007) Ixodes ticks belonging to the Ixodes ricinus complex encode a family of anticomplement proteins. Insect Mol Biol 16:155–166PubMedCrossRef

Dandache P, Nadelman RB (2008) Erythema migrans. Infect Dis Clin N Am 22:235–260 viCrossRef

Das S, Banerjee G, DePonte K et al (2001) Salp25D, an Ixodes scapularis antioxidant, is 1 of 14 immunodominant antigens in engorged tick salivary glands. J Infect Dis 184:1056–1064PubMedCrossRef

Dennis VA, Dixit S, O’Brien SM et al (2009) Live Borrelia burgdorferi spirochetes elicit inflammatory mediators from human monocytes via the Toll-like receptor signaling pathway. Infect Immun 77:1238–1245PubMedCrossRef

Ding W, Huang X, Yang X et al (2000) Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA. J Mol Biol 302:1153–1164PubMedCrossRef

Dressler F, Whalen JA, Reinhardt BN et al (1993) Western blotting in the serodiagnosis of Lyme disease. J Infect Dis 167:392–400PubMedCrossRef

Drouin EE, Glickstein L, Kwok WW et al (2008) Searching for borrelial T cell epitopes associated with antibiotic-refractory Lyme arthritis. Mol Immunol 45:2323–2332PubMedCrossRef

Dykhuizen DE, Baranton G (2001) The implications of a low rate of horizontal transfer in Borrelia. Trends Microbiol 9:344–350PubMedCrossRef

Earnhart CG, Marconi RT (2007a) Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens. Vaccine 25:3419–3427PubMedCrossRef

Earnhart CG, Marconi RT (2007b) An octavalent Lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences. Hum Vaccin 3:281–289PubMed

Earnhart CG, Marconi RT (2007c) OspC phylogenetic analyses support the feasibility of a broadly protective polyvalent chimeric Lyme disease vaccine. Clin Vaccine Immunol 14:628–634PubMedCrossRef

Earnhart CG, Buckles EL, Dumler JS et al (2005) Demonstration of OspC type diversity in invasive human lyme disease isolates and identification of previously uncharacterized epitopes that define the specificity of the OspC murine antibody response. Infect Immun 73:7869–7877PubMedCrossRef

Ekerfelt C, Forsberg P, Svenvik M et al (1999) Asymptomatic Borrelia-seropositive individuals display the same incidence of Borrelia-specific interferon-gamma (IFN-gamma)-secreting cells in blood as patients with clinical Borrelia infection. Clin Exp Immunol 115:498–502PubMedCrossRef

Embers ME, Alvarez X, Ooms T et al (2008) The failure of immune response evasion by linear plasmid 28–1-deficient Borrelia burgdorferi is attributable to persistent expression of an outer surface protein. Infect Immun 76:3984–3991PubMedCrossRef

Exner MM, Wu X, Blanco DR et al (2000) Protection elicited by native outer membrane protein Oms66 (p66) against host-adapted Borrelia burgdorferi: conformational nature of bactericidal epitopes. Infect Immun 68:2647–2654PubMedCrossRef

Fikrig E, Barthold SW, Kantor FS et al (1990) Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 250:553–556PubMedCrossRef

Fikrig E, Barthold SW, Kantor FS et al (1991) Protection of mice from Lyme borreliosis by oral vaccination with Escherichia coli expressing OspA. J Infect Dis 164:1224–1227PubMedCrossRef

Fikrig E, Barthold SW, Marcantonio N et al (1992a) Roles of OspA, OspB, and flagellin in protective immunity to Lyme borreliosis in laboratory mice. Infect Immun 60:657–661PubMed

Fikrig E, Telford SR 3rd, Barthold SW et al (1992b) Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proc Natl Acad Sci USA 89:5418–5421PubMedCrossRef

Fikrig E, Barthold SW, Sun W et al (1997) Borrelia burgdorferi P35 and P37 proteins, expressed in vivo, elicit protective immunity. Immunity 6:531–539PubMedCrossRef

Fikrig E, Chen M, Barthold SW et al (1999) Borrelia burgdorferi erpT expression in the arthropod vector and murine host. Mol Microbiol 31:281–290PubMedCrossRef

Fiserova L, Cerna K, Horka H et al (2008) Two ways of experimental infection of Ixodes ricinus ticks (Acari: Ixodidae) with spirochetes of Borrelia burgdorferi sensu lato complex. Folia Parasitol 55:150–154PubMed

Francischetti IM, Valenzuela JG, Andersen JF et al (2002) Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex. Blood 99:3602–3612PubMedCrossRef

Garon CF, Dorward DW, Corwin MD (1989) Structural features of Borrelia burgdorferi—the Lyme disease spirochete: silver staining for nucleic acids. Scanning Microsc Suppl 3:109–115PubMed

Gilmore RD Jr, Mbow ML (1999) Conformational nature of the Borrelia burgdorferi B31 outer surface protein C protective epitope. Infect Immun 67:5463–5469PubMed

Gilmore RD Jr, Kappel KJ, Dolan MC et al (1996) Outer surface protein C (OspC), but not P39, is a protective immunogen against a tick-transmitted Borrelia burgdorferi challenge: evidence for a conformational protective epitope in OspC. Infect Immun 64:2234–2239PubMed

Gilmore RD Jr, Murphree RL, James AM et al (1999) The Borrelia burgdorferi 37-kilodalton immunoblot band (P37) used in serodiagnosis of early Lyme disease is the flaA gene product. J Clin Microbiol 37:548–552PubMed

Girschick HJ, Huppertz HI, Russmann H et al (1996) Intracellular persistence of Borrelia burgdorferi in human synovial cells. Rheumatol Int 16:125–132PubMedCrossRef

Grab DJ, Lanners H, Martin LN et al (1999) Interaction of Borrelia burgdorferi with peripheral blood fibrocytes, antigen-presenting cells with the potential for connective tissue targeting. Mol Med 5:46–54PubMedCrossRef

Gross DM, Forsthuber T, Tary-Lehmann M et al (1998) Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281:703–706PubMedCrossRef

Gruntar I, Malovrh T, Murgia R et al (2001) Conversion of Borrelia garinii cystic forms to motile spirochetes in vivo. APMIS 109:383–388PubMedCrossRef

Guo BP, Brown EL, Dorward DW et al (1998) Decorin-binding adhesins from Borrelia burgdorferi. Mol Microbiol 30:711–723PubMedCrossRef

Hagman KE, Lahdenne P, Popova TG et al (1998) Decorin-binding protein of Borrelia burgdorferi is encoded within a two-gene operon and is protective in the murine model of Lyme borreliosis. Infect Immun 66:2674–2683PubMed

Hagman KE, Yang X, Wikel SK et al (2000) Decorin-binding protein A (DbpA) of Borrelia burgdorferi is not protective when immunized mice are challenged via tick infestation and correlates with the lack of DbpA expression by B. burgdorferi in ticks. Infect Immun 68:4759–4764PubMedCrossRef

Hanson MS, Cassatt DR, Guo BP et al (1998) Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infect Immun 66:2143–2153PubMed

Hanson MS, Patel NK, Cassatt DR et al (2000) Evidence for vaccine synergy between Borrelia burgdorferi decorin binding protein A and outer surface protein A in the mouse model of lyme borreliosis. Infect Immun 68:6457–6460PubMedCrossRef

Hitt E (2002) Poor sales trigger vaccine withdrawal. Nat Med 8:311–312PubMedCrossRef

Hojgaard A, Eisen RJ, Piesman J (2008) Transmission dynamics of Borrelia burgdorferi s.s. during the key third day of feeding by nymphal Ixodes scapularis (Acari: Ixodidae). J Med Entomol 45:732–736PubMedCrossRef

Hovius JW, de Jong MA, den Dunnen J et al (2008) Salp15 binding to DC-SIGN inhibits cytokine expression by impairing both nucleosome remodeling and mRNA stabilization. PLoS Pathog 4:e31PubMedCrossRef

Humair P, Gern L (2000) The wild hidden face of Lyme borreliosis in Europe. Microbes Infect 2:915–922PubMedCrossRef

Ikushima M, Matsui K, Yamada F et al (2000) Specific immune response to a synthetic peptide derived from outer surface protein C of Borrelia burgdorferi predicts protective borreliacidal antibodies. FEMS Immunol Med Microbiol 29:15–21PubMedCrossRef

Jarefors S, Janefjord CK, Forsberg P et al (2007) Decreased up-regulation of the interleukin-12Rbeta2-chain and interferon-gamma secretion and increased number of forkhead box P3-expressing cells in patients with a history of chronic Lyme borreliosis compared with asymptomatic Borrelia-exposed individuals. Clin Exp Immunol 147:18–27PubMed

Jobe DA, Lovrich SD, Schell RF et al (2003) C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease. Clin Diagn Lab Immunol 10:573–578PubMed

Johnson RC, Hyde FW, Rumpel CM (1984) Taxonomy of the Lyme disease spirochetes. Yale J Biol Med 57:529–537PubMed

Johnson RC, Kodner C, Russell M (1986a) Active immunization of hamsters against experimental infection with Borrelia burgdorferi. Infect Immun 54:897–898PubMed

Johnson RC, Kodner CL, Russell ME (1986b) Vaccination of hamsters against experimental infection with Borrelia burgdorferi. Zentralbl Bakteriol Mikrobiol Hyg A 263:45–48PubMed

Jovicic V, Grego EM, Lako BL et al (2003) Improved serodiagnosis of early Lyme borreliosis: immunoblot with local Borrelia afzelii strain. APMIS 111:1053–1059PubMedCrossRef

Juncadella IJ, Garg R, Ananthnarayanan SK et al (2007) T-cell signaling pathways inhibited by the tick saliva immunosuppressor, Salp15. FEMS Immunol Med Microbiol 49:433–438PubMedCrossRef

Kalish RA, Leong JM, Steere AC (1993) Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect Immun 61:2774–2779PubMed

Klempner MS, Noring R, Rogers RA (1993) Invasion of human skin fibroblasts by the Lyme disease spirochete, Borrelia burgdorferi. J Infect Dis 167:1074–1081PubMedCrossRef

Kochi SK, Johnson RC (1988) Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway. Infect Immun 56:314–321PubMed

Kochi SK, Johnson RC, Dalmasso AP (1991) Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi. Role of antibody in formation of an effective membrane attack complex. J Immunol 146:3964–3970PubMed

Koide S, Yang X, Huang X et al (2005) Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA. J Mol Biol 350:290–299PubMedCrossRef

Korshus JB, Munderloh UG, Bey RF et al (2004) Experimental infection of dogs with Borrelia burgdorferi sensu stricto using Ixodes scapularis ticks artificially infected by capillary feeding. Med Microbiol Immunol 193:27–34PubMedCrossRef

Kotsyfakis M, Sa-Nunes A, Francischetti IM et al (2006) Antiinflammatory and immunosuppressive activity of sialostatin L, a salivary cystatin from the tick Ixodes scapularis. J Biol Chem 281:26298–26307PubMedCrossRef

Kotsyfakis M, Karim S, Andersen JF et al (2007) Selective cysteine protease inhibition contributes to blood-feeding success of the tick Ixodes scapularis. J Biol Chem 282:29256–29263PubMedCrossRef

Kotsyfakis M, Anderson JM, Andersen JF et al (2008) Cutting edge: Immunity against a “silent” salivary antigen of the Lyme vector Ixodes scapularis impairs its ability to feed. J Immunol 181:5209–5212PubMed

Kraiczy P, Skerka C, Brade V et al (2001a) Further characterization of complement regulator-acquiring surface proteins of Borrelia burgdorferi. Infect Immun 69:7800–7809PubMedCrossRef

Kraiczy P, Skerka C, Kirschfink M et al (2001b) Immune evasion of Borrelia burgdorferi by acquisition of human complement regulators FHL-1/reconectin and Factor H. Eur J Immunol 31:1674–1684PubMedCrossRef

Krupka M, Belakova J, Sebestova M et al (2005) Isolation and purification of recombinant outer surface protein C (rOspC) of Borrelia burgdorferi sensu lato. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149:261–264PubMed

Krupka M, Raska M, Belakova J et al (2007) Biological aspects of Lyme disease spirochetes: unique bacteria of the Borrelia burgdorferi species group. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 151:175–186PubMed

Krupka M, Raska M, Horynova M et al. (2008) Preparation of recombinant non-lipidated apyrogenic Borrelia burgdorferi Outer surface protein C. Alergie 10(suppl 2):88 (in Czech)

Kurtenbach K, Dizij A, Voet P et al (1997) Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies. Vaccine 15:1670–1674PubMedCrossRef

Kurtenbach K, Hanincova K, Tsao JI et al (2006) Fundamental processes in the evolutionary ecology of Lyme borreliosis. Nat Rev Microbiol 4:660–669PubMedCrossRef

Kurtti TJ, Munderloh UG, Krueger DE et al (1993) Adhesion to and invasion of cultured tick (Acarina: Ixodidae) cells by Borrelia burgdorferi (Spirochaetales: Spirochaetaceae) and maintenance of infectivity. J Med Entomol 30:586–596PubMed

Kyckova K, Kopecky J (2006) Effect of tick saliva on mechanisms of innate immune response against Borrelia afzelii. J Med Entomol 43:1208–1214PubMedCrossRef

Labandeira-Rey M, Baker EA, Skare JT (2001) VraA (BBI16) protein of Borrelia burgdorferi is a surface-exposed antigen with a repetitive motif that confers partial protection against experimental Lyme borreliosis. Infect Immun 69:1409–1419PubMedCrossRef

LaFleur RL, Dant JC, Wasmoen TL et al (2009) Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. Clin Vaccine Immunol 16:253–259PubMedCrossRef

Lawrenz MB, Wooten RM, Norris SJ (2004) Effects of vlsE complementation on the infectivity of Borrelia burgdorferi lacking the linear plasmid lp28–1. Infect Immun 72:6577–6585PubMedCrossRef

Leboulle G, Crippa M, Decrem Y et al (2002) Characterization of a novel salivary immunosuppressive protein from Ixodes ricinus ticks. J Biol Chem 277:10083–10089PubMedCrossRef

Levy SA (2002) Use of a C6 ELISA test to evaluate the efficacy of a whole-cell bacterin for the prevention of naturally transmitted canine Borrelia burgdorferi infection. Vet Ther 3:420–424PubMed

Liang FT, Jacobs MB, Bowers LC et al (2002) An immune evasion mechanism for spirochetal persistence in Lyme borreliosis. J Exp Med 195:415–422PubMedCrossRef

Liang FT, Yan J, Mbow ML et al (2004) Borrelia burgdorferi changes its surface antigenic expression in response to host immune responses. Infect Immun 72:5759–5767PubMedCrossRef

Livengood JA, Gilmore RD Jr (2006) Invasion of human neuronal and glial cells by an infectious strain of Borrelia burgdorferi. Microbes Infect 8:2832–2840PubMedCrossRef

Lovrich SD, Jobe DA, Schell RF et al (2005) Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters. Clin Diagn Lab Immunol 12:746–751PubMed

Lovrich SD, La Fleur RL, Jobe DA et al (2007) Borreliacidal OspC antibody response of canines with Lyme disease differs significantly from that of humans with Lyme disease. Clin Vaccine Immunol 14:635–637PubMedCrossRef

Luke CJ, Carner K, Liang X et al (1997) An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. J Infect Dis 175:91–97PubMedCrossRef

Lunemann JD, Zarmas S, Priem S et al (2001) Rapid typing of Borrelia burgdorferi sensu lato species in specimens from patients with different manifestations of Lyme borreliosis. J Clin Microbiol 39:1130–1133PubMedCrossRef

Ma Y, Sturrock A, Weis JJ (1991) Intracellular localization of Borrelia burgdorferi within human endothelial cells. Infect Immun 59:671–678PubMed

MacDonald AB (2006a) Plaques of Alzheimer’s disease originate from cysts of Borrelia burgdorferi, the Lyme disease spirochete. Med Hypotheses 67:592–600PubMedCrossRef

MacDonald AB (2006b) Spirochetal cyst forms in neurodegenerative disorders, hiding in plain sight. Med Hypotheses 67:819–832PubMedCrossRef

Malawista SE, de Boisfleury Chevance A (2008) Clocking the Lyme spirochete. PLoS One 3:e1633PubMedCrossRef

Marconi RT, Earnhart CG (2010) Lyme disease vaccines. In: Samuels DS, Radolf JD (eds) Borrelia, molecular biology, host interaction and pathogenesis. Caister Academic Press, Norfolk

Miklossy J, Kasas S, Zurn AD et al (2008) Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis. J Neuroinflammation 5:40PubMedCrossRef

Montgomery RR, Nathanson MH, Malawista SE (1993) The fate of Borrelia burgdorferi, the agent for Lyme disease, in mouse macrophages. Destruction, survival, recovery. J Immunol 150:909–915PubMed

Montgomery RR, Lusitani D, De Boisfleury Chevance A et al (2004) Tick saliva reduces adherence and area of human neutrophils. Infect Immun 72:2989–2994PubMedCrossRef

Mullegger RR, McHugh G, Ruthazer R et al (2000) Differential expression of cytokine mRNA in skin specimens from patients with erythema migrans or acrodermatitis chronica atrophicans. J Invest Dermatol 115:1115–1123PubMedCrossRef

Murgia R, Cinco M (2004) Induction of cystic forms by different stress conditions in Borrelia burgdorferi. APMIS 112:57–62PubMedCrossRef

Murgia R, Piazzetta C, Cinco M (2002) Cystic forms of Borrelia burgdorferi sensu lato: induction, development, and the role of RpoS. Wien Klin Wochenschr 114:574–579PubMed

Narasimhan S, Koski RA, Beaulieu B et al (2002) A novel family of anticoagulants from the saliva of Ixodes scapularis. Insect Mol Biol 11:641–650PubMedCrossRef

Nazario S, Das S, de Silva AM et al (1998) Prevention of Borrelia burgdorferi transmission in guinea pigs by tick immunity. Am J Trop Med Hyg 58:780–785PubMed

Pachner AR, Basta J, Delaney E et al (1995) Localization of Borrelia burgdorferi in murine Lyme borreliosis by electron microscopy. Am J Trop Med Hyg 52:128–133PubMed

Pal U, Li X, Wang T et al (2004) TROSPA, an Ixodes scapularis receptor for Borrelia burgdorferi. Cell 119:457–468PubMedCrossRef

Panelius J, Meri T, Seppala I et al (2008) Outer surface protein E antibody response and its effect on complement factor H binding to OspE in Lyme borreliosis. Microbes Infect 10:135–142PubMedCrossRef

Pechova J, Stepanova G, Kovar L et al (2002) Tick salivary gland extract-activated transmission of Borrelia afzelii spirochaetes. Folia Parasitol 49:153–159PubMed

Persing DH, Rutledge BJ, Rys PN et al (1994) Target imbalance: disparity of Borrelia burgdorferi genetic material in synovial fluid from Lyme arthritis patients. J Infect Dis 169:668–672PubMedCrossRef

Petzke MM, Brooks A, Krupna MA et al (2009) Recognition of Borrelia burgdorferi, the Lyme disease spirochete, by TLR7 and TLR9 induces a type I IFN response by human immune cells. J Immunol 183:5279–5292PubMedCrossRef

Piesman J, Dolan MC (2002) Protection against Lyme disease spirochete transmission provided by prompt removal of nymphal Ixodes scapularis (Acari: Ixodidae). J Med Entomol 39:509–512PubMedCrossRef

Policastro PF, Schwan TG (2003) Experimental infection of Ixodes scapularis larvae (Acari: Ixodidae) by immersion in low passage cultures of Borrelia burgdorferi. J Med Entomol 40:364–370PubMedCrossRef

Pozsgay V, Kubler-Kielb J (2007) Synthesis of an experimental glycolipoprotein vaccine against Lyme disease. Carbohydr Res 342:621–626PubMedCrossRef

Preac-Mursic V, Wilske B, Patsouris E et al (1992) Active immunization with pC protein of Borrelia burgdorferi protects gerbils against B. burgdorferi infection. Infection 20:342–349PubMedCrossRef

Prevot PP, Adam B, Boudjeltia KZ et al (2006) Anti-hemostatic effects of a serpin from the saliva of the tick Ixodes ricinus. J Biol Chem 281:26361–26369PubMedCrossRef

Probert WS, Crawford M, Cadiz RB et al (1997) Immunization with outer surface protein (Osp) A, but not OspC, provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi. J Infect Dis 175:400–405PubMedCrossRef

Ramamoorthi N, Narasimhan S, Pal U et al (2005) The Lyme disease agent exploits a tick protein to infect the mammalian host. Nature 436:573–577PubMedCrossRef

Rittig MG, Krause A, Haupl T et al (1992) Coiling phagocytosis is the preferential phagocytic mechanism for Borrelia burgdorferi. Infect Immun 60:4205–4212PubMed

Rojko T, Ruzic-Sabljic E, Strle F et al (2005) Prevalence and incidence of Lyme borreliosis among Slovene forestry workers during the period of tick activity. Wien Klin Wochenschr 117:219–225PubMedCrossRef

Sanogo YO, Reipert S, Halouzka J et al (2000) Isolation and morphological characterization of mosquito spirochetes from a Lyme disease endemic area. Ann N Y Acad Sci 916:672–675PubMedCrossRef

Sa-Nunes A, Bafica A, Lucas DA et al (2007) Prostaglandin E2 is a major inhibitor of dendritic cell maturation and function in Ixodes scapularis saliva. J Immunol 179:1497–1505PubMed

Schaible UE, Kramer MD, Eichmann K et al (1990) Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc Natl Acad Sci USA 87:3768–3772PubMedCrossRef

Schaible UE, Wallich R, Kramer MD et al (1993) Immune sera to individual Borrelia burgdorferi isolates or recombinant OspA thereof protect SCID mice against infection with homologous strains but only partially or not at all against those of different OspA/OspB genotype. Vaccine 11:1049–1054PubMedCrossRef

Scheiblhofer S, Weiss R, Durnberger H et al (2003) A DNA vaccine encoding the outer surface protein C from Borrelia burgdorferi is able to induce protective immune responses. Microbes Infect 5:939–946PubMedCrossRef

Schulte-Spechtel U, Fingerle V, Goettner G et al (2006) Molecular analysis of decorin-binding protein A (DbpA) reveals five major groups among European Borrelia burgdorferi sensu lato strains with impact for the development of serological assays and indicates lateral gene transfer of the dbpA gene. Int J Med Microbiol 296(suppl 40):250–266PubMedCrossRef

Seemanapalli SV, Xu Q, McShan K et al (2010) Outer surface protein C is a dissemination-facilitating factor of Borrelia burgdorferi during mammalian infection. PLoS ONE 5:e15830PubMedCrossRef

Shin JJ, Glickstein LJ, Steere AC (2007) High levels of inflammatory chemokines and cytokines in joint fluid and synovial tissue throughout the course of antibiotic-refractory lyme arthritis. Arthritis Rheum 56:1325–1335PubMedCrossRef

Shin OS, Isberg RR, Akira S et al (2008) Distinct roles for MyD88 and Toll-like receptors 2, 5, and 9 in phagocytosis of Borrelia burgdorferi and cytokine induction. Infect Immun 76:2341–2351PubMedCrossRef

Sigal LH, Zahradnik JM, Lavin P et al (1998) A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med 339:216–222PubMedCrossRef

Sikand VK, Halsey N, Krause PJ et al (2001) Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial. Pediatrics 108:123–128PubMedCrossRef

Sjowall J, Carlsson A, Vaarala O et al (2005) Innate immune responses in Lyme borreliosis: enhanced tumour necrosis factor-alpha and interleukin-12 in asymptomatic individuals in response to live spirochetes. Clin Exp Immunol 141:89–98PubMedCrossRef

Skallova A, Iezzi G, Ampenberger F et al (2008) Tick saliva inhibits dendritic cell migration, maturation, and function while promoting development of Th2 responses. J Immunol 180:6186–6192PubMed

Srivastava SY, de Silva AM (2008) Reciprocal expression of ospA and ospC in single cells of Borrelia burgdorferi. J Bacteriol 190:3429–3433PubMedCrossRef

Srivastava SY, de Silva AM (2009) Characterization of Borrelia burgdorferi aggregates. Vector Borne Zoonotic Dis 9:323–329PubMedCrossRef

Steere AC, Schoen RT, Taylor E (1987) The clinical evolution of Lyme arthritis. Ann Intern Med 107:725–731PubMed

Steere AC, Sikand VK, Meurice F et al (1998) Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med 339:209–215PubMedCrossRef

Steere AC, Gross D, Meyer AL et al (2001) Autoimmune mechanisms in antibiotic treatment-resistant lyme arthritis. J Autoimmun 16:263–268PubMedCrossRef

Steere AC, Sikand VK, Schoen RT et al (2003) Asymptomatic infection with Borrelia burgdorferi. Clin Infect Dis 37:528–532PubMedCrossRef

Steere AC, McHugh G, Damle N et al (2008) Prospective study of serologic tests for Lyme disease. Clin Infect Dis 47:188–195PubMedCrossRef

Stover CK, Bansal GP, Hanson MS et al (1993) Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med 178:197–209PubMedCrossRef

Stricker RB (2007) Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with Lyme disease. Clin Infect Dis 45:149–157PubMedCrossRef

Stricker RB, Johnson L (2008) Re: prolonged Lyme disease treatment: enough is enough. Neurology 71:1380 (author reply 1380–1381)

Stubs G, Fingerle V, Wilske B et al (2009) Acylated cholesteryl galactosides are specific antigens of borrelia causing Lyme disease and frequently induce antibodies in late stages of disease. J Biol Chem 284:13326–13334PubMedCrossRef

Stubs G, Rupp B, Schumann RR et al (2010) Chemoenzymatic synthesis of a glycolipid library and elucidation of the antigenic epitope for construction of a vaccine against Lyme disease. Chemistry 16:3536–3544PubMedCrossRef

Thomas DD, Cadavid D, Barbour AG (1994) Differential association of Borrelia species with cultured neural cells. J Infect Dis 169:445–448PubMedCrossRef

Tilly K, Bestor A, Jewett MW et al (2007) Rapid clearance of Lyme disease spirochetes lacking OspC from skin. Infect Immun 75:1517–1519PubMedCrossRef

Tilly K, Bestor A, Dulebohn DP et al (2009) OspC-independent infection and dissemination by host-adapted Borrelia burgdorferi. Infect Immun 77:2672–2682PubMedCrossRef

Topfer KH, Straubinger RK (2007) Characterization of the humoral immune response in dogs after vaccination against Lyme borreliosis agent: a study with five commercial vaccines using two different vaccination schedules. Vaccine 25:314–326PubMedCrossRef

Tuhackova J, Belakova J, Krupka M et al (2005) Testing of the Biocan B inj. ad us. vet. vaccine and development of the new recombinant vaccine against canine borreliosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149:297–302PubMed

Tuominen-Gustafsson H, Penttinen M, Hytönen J et al (2006) Use of CFSE staining of borreliae in studies on the interaction between borreliae and human neutrophils. BMC Microbiol 6:92PubMedCrossRef

Tyson KR, Elkins C, de Silva AM (2008) A novel mechanism of complement inhibition unmasked by a tick salivary protein that binds to properdin. J Immunol 180:3964–3968PubMed

Ulbrandt ND, Cassatt DR, Patel NK et al (2001) Conformational nature of the Borrelia burgdorferi decorin binding protein A epitopes that elicit protective antibodies. Infect Immun 69:4799–4807PubMedCrossRef

Valenzuela JG, Charlab R, Mather TN et al (2000) Purification, cloning, and expression of a novel salivary anticomplement protein from the tick, Ixodes scapularis. J Biol Chem 275:18717–18723PubMedCrossRef

Wallich R, Schaible UE, Simon MM et al (1989) Cloning and sequencing of the gene encoding the outer surface protein A (OspA) of a European Borrelia burgdorferi isolate. Nucleic Acids Res 17:8864PubMedCrossRef

Wallich R, Siebers A, Jahraus O et al (2001) DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease. Infect Immun 69:2130–2136PubMedCrossRef

Wallich R, Pattathu J, Kitiratschky V et al (2005) Identification and functional characterization of complement regulator-acquiring surface protein 1 of the Lyme disease spirochetes Borrelia afzelii and Borrelia garinii. Infect Immun 73:2351–2359PubMedCrossRef

Wang IN, Dykhuizen DE, Qiu W et al (1999) Genetic diversity of OspC in a local population of Borrelia burgdorferi sensu stricto. Genetics 151:15–30PubMed

Widhe M, Jarefors S, Ekerfelt C et al (2004) Borrelia-specific interferon-gamma and interleukin-4 secretion in cerebrospinal fluid and blood during Lyme borreliosis in humans: association with clinical outcome. J Infect Dis 189:1881–1891PubMedCrossRef

Wiedemann C, Milward F (1999) Efficacy and safety studies with a new vaccine against Lyme borreliosis in dogs (Merilyme (R)). Tierarztl Umsch 54:242–249

Wikle RE, Fretwell B, Jarecki M et al (2006) Canine Lyme disease: one-year duration of immunity elicited with a canine OspA monovalent Lyme disease vaccine. Int J Appl Res Vet Med 4:23–28

Willett TA, Meyer AL, Brown EL et al (2004) An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope. Proc Natl Acad Sci USA 101:1303–1308PubMedCrossRef

Wilske B, Preac-Mursic V, Jauris S et al (1993) Immunological and molecular polymorphisms of OspC, an immunodominant major outer surface protein of Borrelia burgdorferi. Infect Immun 61:2182–2191PubMed

Wormser GP, McKenna D, Carlin J et al (2005) Brief communication: hematogenous dissemination in early Lyme disease. Ann Intern Med 142:751–755PubMed

Wormser GP, Dattwyler RJ, Shapiro ED et al (2006) The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43:1089–1134PubMedCrossRef

Xu Q, Seemanapalli SV, McShan K et al (2006) Constitutive expression of outer surface protein C diminishes the ability of Borrelia burgdorferi to evade specific humoral immunity. Infect Immun 74:5177–5184PubMedCrossRef

Xu Q, McShan K, Liang FT (2007a) Identification of an ospC operator critical for immune evasion of Borrelia burgdorferi. Mol Microbiol 64:220–231PubMedCrossRef

Xu Q, Seemanapalli SV, Reif KE et al (2007b) Increasing the recruitment of neutrophils to the site of infection dramatically attenuates Borrelia burgdorferi infectivity. J Immunol 178:5109–5115PubMed

Xu Q, McShan K, Liang FT (2008a) Essential protective role attributed to the surface lipoproteins of Borrelia burgdorferi against innate defences. Mol Microbiol 69:15–29PubMedCrossRef

Xu Q, McShan K, Liang FT (2008b) Verification and dissection of the ospC operator by using flaB promoter as a reporter in Borrelia burgdorferi. Microb Pathog 45:70–78PubMedCrossRef

Zakovska A, Capkova L, Sery O et al (2006) Isolation of Borrelia afzelii from overwintering Culex pipiens biotype molestus mosquitoes. Ann Agric Environ Med 13:345–348PubMed

Zambrano MC, Beklemisheva AA, Bryksin AV et al (2004) Borrelia burgdorferi binds to, invades, and colonizes native type I collagen lattices. Infect Immun 72:3138–3146PubMedCrossRef

Zhang JR, Norris SJ (1998) Genetic variation of the Borrelia burgdorferi gene vlsE involves cassette-specific, segmental gene conversion. Infect Immun 66:3698–3704PubMed

Zhioua E, Rodhain F, Binet P et al (1997) Prevalence of antibodies to Borrelia burgdorferi in forestry workers of Ile de France, France. Eur J Epidemiol 13:959–962PubMedCrossRef

Titel: Prevention of Lyme Disease: Promising Research or Sisyphean Task?
verfasst von: Michal Krupka
Katerina Zachova
Evzen Weigl
Milan Raska
Publikationsdatum: 01.08.2011
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Archivum Immunologiae et Therapiae Experimentalis / Ausgabe 4/2011
Print ISSN: 0004-069X
Elektronische ISSN: 1661-4917
DOI: https://doi.org/10.1007/s00005-011-0128-z

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten